Website designed by: Vanmala VONGKINGKEO
Icons made by Twitter from www.flaticon.com
We are proud to share the Cardiateam’s first consortium article on experimental models of Diabetic CardioMyopathy (DCM) : “Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality “ published in Cardiovascular Research, Volume 119, Issue 5, May 2023, Pages 1130–1145. In this review article we identify the current limitations of rodent models and discuss how future mechanistic and preclinical studies should integrate key confounding factors to better mimic the DCM phenotype. The article is free of access: https://doi.org/10.1093/cvr/cvac152 Have a read!
We have set up a page on LinkedIn! Make sure to follow us in order to stay updated on our project!
Hybrid meetings- Hybrid group photos! CARDIATEAM had its consortium meeting on 23-24th March, hosted by CIBER in Madrid! Lots of existing discussions on first preliminary results.
After two years of online meetings we finally had the pleasure to meet again in person this August on the occasion of the annual conference of the European Society of Cardiology. CARDIATEAM organised a short consortium meeting on the premises of the congress which allowed us to discuss and plan upcoming challenges.
All present members of CARDIATEAM enjoyed seeing each other again and are looking forward to our next meeting which will also be hold in presence in Madrid, next March.
The third period (P3) of CARDIATEAM continued with the effects and sanitary measures of the COVID-19 pandemic impacting on the recruitment rate of the CARDIATEAM study. However, by the end of P3, WP2 has achieved in collaboration with WP3, WP4 and WP5, the implementation and adaptation of the study protocol and all related documents in all participating countries. To ensure the accuracy/integrity of the collected data and a harmonious conduction of the study throughout the recruiting sites, a global monitoring has been implemented.
The main achievement for the P3 has been to open centers in all countries involved in the study. Eleven sites have been initiated and other sites initiation visits are planned before summer 2022. P3 ended with a total of 250 patients recruited and first year follow-up have been performed for the first recruits.
The required infrastructure to collect imaging data in the CARDIATEAM cohort has been installed. The CARDIATEAM web-based database platform is operational and has been successfully validated. Participating centres are being trained and certified by transferring collected data to the imaging core labs and uploading the measurements to a central repository. All data flows are in place and quality assurance measures have been implemented. Hereto, a certification process has been put in place as well as continuous monitoring of the core-lab performance. As the rate of patient inclusion has increased in P3, the data-flow to and from the web-platform are put to the test, and modifications and further improvements were implemented on the go, based on the feedback of imaging core-labs and imaging centers.
The database which will collect all clinical, imaging and omics data of the recruited patients has been set up and structured. We have developed an eCRF system to collect clinical data from recruited patients. This system contains functionality allowing the manual, expert review of registered data to avoid errors and missing data. Training sessions for clinical research assistants on the tool have been organised at each of the different sites. A data transfer protocol has been implemented between the main data processing partners to securely push validated records into the central database. Pipelines for processing of clinical data into the database have been established and web-based mining tools to query the content of the database to allow live monitoring of collected data have been developed. The unsupervised machine learning methodology required to analyze the future deep phenotypic data has been set-up and tested.
Like in previous periods, sample collection kits have been distributed to the already recruiting centers As biological sample collection suffers from the delay in patient’s recruitment (see above), the analyses on the omics measurement have not started yet however a first batch of samples has been sent for a successful quality check to LIH .
Concerning animal models, WP7 partners have now finalised the overview of existing preclinical models of metabolic disorders pertinent to the project and submitted a first joint publication. Two models of interest have been selected for the use within the consortium and a join protocol is being finalized to start mid-RP4.
The CARDIATEAM consortium organised with the help of Prof Giuseppe Matullo from Partner 12, the University of Turino, its first Scientific Exchange Meeting on 22nd of April 2021.
The topic of this first Scientific Exchange in a virtual format (due to the ongoing pandemic situation) was on “Omics investigation in the frame of the CARDIATEAM consortium”. The talks were given by the members of the CARDIATEAM consortium on the latest results on the use of omics in the cardiovascular field:
1. Giuseppe Matullo form Partner 12 University of Turin (Italy) : Introduction to genomics and epigenomics investigations in cardiometabolic diseases
2. Flora Sam from Partner 21 Lilly (USA): The transcriptome in cardiometabolic phenotypes – insights for diabetic cardiomyopathy and heart failure?
3. Rui Wang-Sattler from Partner 13 Helmholtz Forschungszentrum (Germany): Identification and validation of candidate biomarkers of metabolic diseases (pre-diabetes, T2D, MI, CKD) by metabolomics.
The talks were then followed by fruitful discussions on the use of Omics to deep-phenotype the patients recruited prospectively in the CARDIATEAM clinical study of the project.
The Omic strategies will be part of the topics discussed during the upcoming Scientific Advisory Board meeting scheduled in the 2nd of July 2021.
Our CARDIATEAM study was initially thought to start in March 2020 but had then been hit as the rest of the world by the COVID pandemic and its measures which were particularly affecting all clinical activities, impacting on the start of our study.
We now have the immense pleasure to announce that on Friday 2nd of October 2020 we were able to include our first patient for the CARDIATEAM study! The patient has been recruited at the Mondor APHP Hospital in Creteil and went through all scheduled exams.
The other participating recruitment centers have already scheduled patient visits in the coming weeks, so the study is officially kicked off now.
With the aim to instruct the teams of the clinical centers who will participate to the CARDIATEAM study, a webinar had been organised at the end of November 2019.
Prof Genevieve DERUMEAUX (Inserm), Prof. Javier BERMEJO (CIBER) , Prof Alban REDHEUIL (APHP) and Prof. Jan D’HOOGE (KU Leuven) gave lectures on the different imaging aspects of the study.
Due to the COVID -19 situation the project decided to postpone to a later date the consortium meeting that had been scheduled originally to take place on 2nd and 3rd of April 2020, hosted by CIBER in Madrid.
The first CARDIATEAM project meeting took place in March 2019!
This first gathering was an important and exciting milestone: the beginning of our innovative project about diabetic cardiomyopathy.
All the members of our consortium are eager to collaborate and work on an innovative approach to assess whether Type 2 Diabetes has an influence on the development of diabetic cardiomyopathy and if it is unique and distinct from the other types of heart failure.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 821508.
See more on Cordis portal.
The contents of this website and the view expressed in the news and publications are the sole responsibility of the authors and under no circumstances can be regarded as reflecting the position of the European Union.